BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Abliva - ECPv6.15.14//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://abliva.com
X-WR-CALDESC:Händelser för Abliva
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240512
DTEND;VALUE=DATE:20240515
DTSTAMP:20260405T223527
CREATED:20240122T102118Z
LAST-MODIFIED:20240513T081946Z
UID:4141-1715472000-1715731199@abliva.com
SUMMARY:Bio€quity Europe
DESCRIPTION:I mitten av maj medverkar Abliva vid mötet Bio€quity Europe i San Sebastán\, Spanien. \n”For more than 20 years\, Bio€quity Europe has been where CEOs and investors gather to network\, partner\, and debate critical issues facing the biotech industry.” \nAblivas VD Ellen Donnelly kommer\, tillsammans med CMO Magnus Hansson\, bland annat att presentera bolaget under eventet. \nFölj länken nedan för mer information.
URL:https://abliva.com/sv/event/bioequity-europe/
LOCATION:Kursaal Elkargunea Center\, Zurriola Hiribidea\, 1\, San Sebastián\, 20002\, Spain
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2024/01/san_sebastian.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240521T160000
DTEND;TZID=Europe/Stockholm:20240521T170000
DTSTAMP:20260405T223527
CREATED:20240502T152707Z
LAST-MODIFIED:20240502T152707Z
UID:5206-1716307200-1716310800@abliva.com
SUMMARY:Virtuellt KOL-event om KL1333 (hålls på engelska)
DESCRIPTION:Join Abliva for a virtual KOL event featuring Amel Karaa\, MD (Massachusetts General Hospital)\, who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently no approved medicines for the systemic disease. \nThe event will focus on Abliva’s lead program\, KL1333\, which has shown clinically meaningful\, early signals of efficacy in mitochondrial disease patients. This novel therapeutic approach modulates the underlying pathophysiology in mitochondrial disease. KL1333 is currently being evaluated in the pivotal Phase 2 FALCON trial\, with interim analysis expected mid-year 2024. KL1333 has Orphan Drug Designation (ODD) in both Europe and the U.S. and Fast Track designation in the U.S. \nRegistration information \nRegister here: https://lifescievents.com/event/abliva/\nA live question and answer session will follow the formal presentation. Ask your question to: questions@lifesciadvisors.com. \nYou are required to register in advance for the webcast. For those who are unable to attend live\, a replay will be available via the link below.
URL:https://abliva.com/sv/event/virtuellt-kol-event-om-kl1333-halls-pa-engelska/
CATEGORIES:Investerarevent,Vetenskapligt event
ATTACH;FMTTYPE=image/png:https://abliva.com/wp-content/uploads/2024/05/Abliva-Social-Media-v2.png
END:VEVENT
END:VCALENDAR